Antibodies

A ‘silver bullet’ for Ebola viruses?

There may be a “silver bullet” for Ebola. Researchers at Vanderbilt University Medical Center and the University of Texas Medical Branch in Galveston (UTMB) reported that they have isolated human monoclonal antibodies from Ebola survivors which can neutralize multiple species of the virus.

James Crowe, M.D., director of the Vanderbilt Vaccine Center, watches graduate...
James Crowe, M.D., director of the Vanderbilt Vaccine Center, watches graduate student Andrew Flyak plate antibody-producing B cells from people in Africa who have survived infection by the Ebola virus.
Source: Vanderbilt University Medical Center

“We thought we would need five different sets of vaccines or five different (drugs),” said James Crowe Jr., M.D., the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center, who led Vanderbilt’s end of the research. “This work suggests there are common elements across different groups of Ebola viruses,” Crowe said. “Maybe we can come up with one therapeutic or one vaccine that would solve all of them.”

“In this study, a remarkably diverse array of virus-specific antibodies was isolated, which appeared to bind to various parts of the envelope protein of the virus,” said UTMB professor Alexander Bukreyev, Ph.D., corresponding author of the paper with Crowe who led the UTMB team. “Some of the antibodies neutralized not only Ebola Bundibugyo virus, but also Ebola Sudan virus and Ebola Zaire virus, similar to that which caused the recent outbreak in West Africa,” Bukreyev said.

Ebola virus disease is spread by contact with contaminated body fluids, including blood and semen. It can cause massive bleeding. The death rate is about 50 percent. The World Health Organization has reported 24 Ebola outbreaks since 1976, the largest of which is thought to have begun in Guinea in December 2013. Of the 28,600 people who had been infected as of this month, 40 percent have died.

Several experimental Ebola vaccines and monoclonal antibody therapies currently are in development. Monoclonal antibodies are generated by clones of a type of white blood cell that have been fused to myeloma (cancer) cells to form fast-growing “hybridomas.” Like heat-seeking missiles, they seek out and destroy their targets, in this case, the Ebola virus.

Unlike vaccines, antibody treatments are meant to provide short-term protection to health care workers and others at risk of exposure. They also could be used as antiviral drugs to treat patients who are already infected with Ebola virus.

Last week, researchers at Albert Einstein College of Medicine in New York reported that “bispecific” monoclonal antibodies they engineered to recognize two species of Ebola virus provided a high degree of protection in mice exposed to two Ebola viral species.

In the current study, Vanderbilt researchers led by graduate student Andrew Flyak, the paper’s first author, used a high-efficiency method they developed to quickly isolate and generate large quantities of monoclonal human antibodies from the blood of survivors of a 2007 outbreak in Uganda who were infected by the Bundibugyo ebolavirus.

Components of the study, which require work with live viruses, were performed by Bukreyev’s team at the Galveston National Laboratory at UTMB, which has biosafety facilities capable of handling Ebola viruses safely.

In addition to neutralizing multiple Ebolavirus species, one of the antibodies also protected guinea pigs from a lethal challenge of virus. Previous therapeutics used re-engineered mouse antibodies. “This work points the way to using fully human antibodies as the next generation of antibody therapeutics,” Crowe said. “From the human antibody work … and the vaccine work that’s being done, it’s clear we can find a protective strategy for Ebola,” he said. “That’s a big step forward.”


Source: Vanderbilt University Medical Center

17.02.2016

Read all latest stories

Related articles

Photo

Tricky virus

Measles infections erase 'immune memory' – vaccination confers protection

Measles infections are not harmless – they can cause disease courses that may be of fatal outcome. Researchers of the Paul-Ehrlich-Institut (PEI) in co-operation with researchers from the UK and…

Photo

EMA recommandation for Ervebo

Ebola: first vaccine to protect against deadly virus

It is an important step towards fighting one of the deadliest viruses known to man: The human medicines committee (CHMP) of the European Medicines Agency (EMA) has recommended granting a conditional…

Photo

Catching flu by the stalk

One step closer to a universal influenza vaccine

Influenza viruses cause substantial health hazards and claim many lives worldwide each year. Vaccines can keep the virus in check, however, they only protect against influenza when they match the…